Invenomic Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Solventum
SOLV
|
+$50M |
| 2 |
Global Payments
GPN
|
+$29.6M |
| 3 |
Aptiv
APTV
|
+$29.1M |
| 4 |
Coursera
COUR
|
+$23.9M |
| 5 |
Newmont
NEM
|
+$23.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
3M
MMM
|
+$38.8M |
| 2 |
Archer Daniels Midland
ADM
|
+$37.9M |
| 3 |
Conagra Brands
CAG
|
+$25.2M |
| 4 |
WEX
WEX
|
+$23M |
| 5 |
SMAR
Smartsheet Inc.
SMAR
|
+$21.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 16.97% |
| 2 | Technology | 15.71% |
| 3 | Healthcare | 12.23% |
| 4 | Communication Services | 9.72% |
| 5 | Energy | 9.45% |
Similar funds
Invenomic Capital Management's Q2 2024 Portfolio in Review
As of Q2 2024, Invenomic Capital Management held 190 positions worth $2.05B, up 9.3% from $1.88B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Invenomic Capital Management deployed $354M of net new capital in Q2 2024, opening 45 new positions and adding to 56 existing holdings. Its largest new stake was Solventum: 824,185 shares worth $43.6M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 17% of assets, down from 17% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was 3M, an estimated $38.8M trimmed.
- Invenomic Capital Management's largest Q2 2024 buy was Solventum: 824,185 shares worth $43.6M.
- Invenomic Capital Management added most to Global Payments in Q2 2024, an estimated $29.6M increase.
- Invenomic Capital Management's biggest Q2 2024 reduction was 3M, cutting an estimated $38.8M.
- Invenomic Capital Management fully exited Archer Daniels Midland in Q2 2024, selling an estimated $37.9M.
- Invenomic Capital Management's ten largest holdings make up 26% of its $2.05B portfolio in Q2 2024.
- Invenomic Capital Management opened 45 new positions and closed 32 in Q2 2024.
- Invenomic Capital Management's portfolio value rose 9.3% quarter-over-quarter to $2.05B.
Based on Invenomic Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.